Recent medicine shortages across Europe have highlighted critical gaps in the resilience and security of our healthcare systems, prompting decisive action from the E...

In this article, Vincenza Pironti, Head of Business Development at Recipharm, explores the latest trends in messenger RNA (mRNA) drug development, dives into the dev...

Even after decades of research and everincreasing R&D spending, the overall success rate of oncology programmes remains low. At an industry level, over $50bn is ...

Inflammatory bowel disease (IBD) is a term for two conditions (Crohn's Disease and Ulcerative Colitis) that are characterised by chronic inflammation of the gastroin...

The increasing global incidence of cancer underscores the urgent need for more effective and targeted treatments. Highly potent active pharmaceutical ingredients (HP...

With autoimmune diseases cumulatively affecting 5 to 10% of the industrial world population, the global market for autoimmune therapeutics is set to grow at a CAGR o...

Complex drug formulations, stringent regulatory standards, and a tough capital landscape are creating pressure for drug developers as they approach clinical trials. ...

When developing a tablet, three widely used technologies are often considered to produce solid dosage forms: direct compression, wet granulation and dry granulation....

Global warming is a critical consequence of using fossil feedstocks to produce plastics and energy. In addition, the reserves of fossil feedstocks are going to run o...

The rise of advanced therapy medicinal products (ATMPs) marks a new era in medicine, offering unprecedented possibilities for treating previously intractable disease...